From: Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
N | Interventions | Phase | Patient(n) | Sponsors | Primary endpoint | Identifier |
---|---|---|---|---|---|---|
1 | Nivolumab | II | 55 | European Organization for Research and Treatment of Cancer—EORTC | 6 m-PFS | NCT03134118 |
2 | Atezolizumab | II | 34 | Hoffmann-La Roche | ORR | NCT04321330 |
3 | Nivolumab | II | 117 | Vanderbilt-Ingram Cancer Center | ORR | NCT03583086 |
4 | Avelumab | II | 55 | National Cancer Institute (NCI) | ORR | NCT03076554 |
5 | Chemotherapy +  Pembrolizumab | IV | 40 | Tangdu Hospital, Fourth Military Medical University Xi'an, Shaanxi, China | ORR | NCT04554524 |
6 | Pembrolizumab Lenvatinib 10Â mg | II | 43 | Medica Scientia Innovation Research | 5Â m-PFS | NCT04710628 |
7 | Toripalimab Chemotherapy | II | 15 | Shanghai Pulmonary Hospital, Shanghai, China | MPRR | NCT04667793 |
8 | Pembrolizumab Radiation | II | 40 | Samsung Medical Center | MPRR | NCT03858582 |
9 | KN046 (PD-L1& CTLA-4 inhibitor) | II | 29 | Weill Medical College of Cornell University | ORR | NCT04925947 |
10 | KN046 (PD-L1& CTLA-4 inhibitor) | II | 66 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | ORR | NCT04469725 |
11 | M7824 (PD-L1& TGF-ß inhibitor) | II | 38 | National Cancer Institute (NCI) | ORR | NCT04417660 |
12 | SO-C101 (IL-15 activator) + Pembrolizumab | I | 200 | SOTIO Biotech AG | DLT | NCT04234113 |
13 | XmAb20717 (PD-1 & CTLA-4 inhibitor) | I | 154 | Xencor, Inc | TRAE | NCT03517488 |
14 | Pembrolizumab Sunitinib Malate (RTK inhibitor) | II | 40 | Ohio State University Comprehensive Cancer Center | ORR | NCT03463460 |